Last reviewed · How we verify

Metronidazole 400 (7 days)

University of Guarulhos · FDA-approved active Small molecule

Metronidazole 400 (7 days) is a Nitroimidazole antibiotic Small molecule drug developed by University of Guarulhos. It is currently FDA-approved for Anaerobic bacterial infections (e.g., intra-abdominal, gynecological, dental), Trichomoniasis, Giardiasis.

Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after being reduced inside microbial cells.

Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after being activated in anaerobic environments. Used for Bacterial vaginosis, Trichomoniasis, Anaerobic bacterial infections.

At a glance

Generic nameMetronidazole 400 (7 days)
SponsorUniversity of Guarulhos
Drug classNitroimidazole antibiotic
TargetBacterial/parasitic DNA
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Metronidazole is a prodrug that requires reduction by anaerobic organisms or parasites to form reactive intermediates that damage DNA and inhibit nucleic acid synthesis. It is effective against anaerobic bacteria and certain protozoan parasites, making it bactericidal and antiprotozoal. The drug has been in clinical use for decades and is considered a first-line agent for anaerobic infections and specific parasitic diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Metronidazole 400 (7 days)

What is Metronidazole 400 (7 days)?

Metronidazole 400 (7 days) is a Nitroimidazole antibiotic drug developed by University of Guarulhos, indicated for Anaerobic bacterial infections (e.g., intra-abdominal, gynecological, dental), Trichomoniasis, Giardiasis.

How does Metronidazole 400 (7 days) work?

Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after being reduced inside microbial cells.

What is Metronidazole 400 (7 days) used for?

Metronidazole 400 (7 days) is indicated for Anaerobic bacterial infections (e.g., intra-abdominal, gynecological, dental), Trichomoniasis, Giardiasis, Amebiasis, Clostridioides difficile infection.

Who makes Metronidazole 400 (7 days)?

Metronidazole 400 (7 days) is developed and marketed by University of Guarulhos (see full University of Guarulhos pipeline at /company/university-of-guarulhos).

What drug class is Metronidazole 400 (7 days) in?

Metronidazole 400 (7 days) belongs to the Nitroimidazole antibiotic class. See all Nitroimidazole antibiotic drugs at /class/nitroimidazole-antibiotic.

What development phase is Metronidazole 400 (7 days) in?

Metronidazole 400 (7 days) is FDA-approved (marketed).

What are the side effects of Metronidazole 400 (7 days)?

Common side effects of Metronidazole 400 (7 days) include Metallic taste, Nausea, Headache, Diarrhea, Peripheral neuropathy (with prolonged use), Disulfiram-like reaction with alcohol.

What does Metronidazole 400 (7 days) target?

Metronidazole 400 (7 days) targets Bacterial/parasitic DNA and is a Nitroimidazole antibiotic.

Related